Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

Abstract: Methods are provided for generating a barcode with embedded colour palette for colour correction of a captured image in digital format. These methods comprise: generating an initial barcode according to a barcode standard and formed by light colour and dark colour encoding units jointly encoding a reference to storage location; splitting a predefined set of reference colours into reference dark and reference light colours depending on contrast threshold; modifying the initial barcode by replacing dark colour encoding units by reference dark colours and light colour encoding units by reference light colours; and updating the storage location with data representing the reference colours included in the modified barcode and positions of said reference colours in the modified barcode. Methods are provided for colour correction based on a barcode determined by said methods. Computer programs and systems are provided which are suitable for performing said barcode generation methods and colour correction methods.

Abstract: Methods for provoking a physiological response in a subject comprising: receiving from sensors an orientation of an HMD of the subject and a parameter indicative of a physiological state of the subject, determining a video signal representing an avatar of the subject in a virtual reality scenario to be displayed on the head mounted display taking into account the orientation of the head mounted display, wherein the video signal includes an indication of a physiological state of the avatar, and sending the video signal to the head mounted display for visualization, optionally accompanied by a suitable audio signal. During a first period, the indication of the physiological state of the avatar substantially corresponds to the measured physiological state, and during a second period the indication of the physiological state of the avatar does not correspond to the measured physiological state. Related computer program and computing systems are also disclosed.

Abstract: Surface having properties for reducing diffuse light due to water condensation, wherein the antifog means consist in atomic aggregates adhered to and dispersed over the surface, wherein the aggregates are selected among the transition metals and the silicon. It is also related to a method for obtaining a surface having properties for reducing diffuse light due to water condensation a wavelength selected in the range from 100 nm to 50 micrometers, comprising the steps of selecting the wavelength, obtaining a glass or polymer surface that has been subjected to optical polishing and adhering to the surface atomic aggregates which are selected among the transition metals and the silicon with a separation between them being lower than or having an order of the selected wavelength selected. Thus a durable antifogging surface is obtained.

Abstract: A method for motor training comprising: receiving from one or more sensors an orientation of a head mounted display of the subject; adapting a base video signal representing an avatar of the subject in a virtual reality to be displayed on the head mounted display wherein the avatar comprises a virtual limb corresponding to the limb that is injured; and sending the base video signal to the head mounted display for visualization. The method further comprises in response to a trigger signal from the subject, sending an exercise video signal representing the avatar in the virtual reality performing an exercise to start the visual rendering of the exercise in the head mounted display, even though the corresponding real limb is substantially immobile and provides no input at all. Such exercise is aimed at rehabilitation of the limb from the injury with the virtual limb corresponding to the immobile limb and it is displayed taking into account the orientation of the head mounted display.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: In a first aspect, the present invention provides a method of measuring attention of a person comprising presenting one or more stimulus aimed at attracting attention of the person; and obtaining positions of the eyes of the person. The method further comprises detecting one or more eye fixations from the obtained positions of the eyes; and measuring the angle of convergence of the eyes over time from the obtained positions of the eyes during one or more of the detected eye fixations.

Abstract: A summation circuit (1) for summing one or more signals received from a photomultiplier array is proposed. The summation circuit comprises one or more readout circuits (5) coupleable to one or more photodiodes of the photomultiplier array (2), respectively, and a channel summing module (50), coupled at one or more outputs of the one or more readout circuits, respectively, to sum the one or more signals provided by the one or more readout circuits. The one or more readout circuits are coupleable to the photodiode of the photomultiplier array. Each readout circuit (5) comprises one or more coefficient controllers (C1, C2) for controlling multiplying coefficients of the received signal. The coefficient controllers may be placed at the input and/or at the output of the readout circuits (5).

Abstract: Signal processing method for histogram generation, and corresponding device and use. The method generates the histogram from a plurality of event detectors that generate event signals as a response to external events, and are connected to a current injection module which is connected to a plurality of capacitors, wherein each histogram bin is univocally assigned to a capacitor. The method includes: during an event time interval corresponding to a bin, the event detectors generate event signals as a response to external events; the current injection module detects said event signals and, for each event signal, generates a corresponding current signal, which is injected in a capacitor assigned to said bin, and stored therein; repeating steps for each successive bin of said histogram; and reading the charge accumulated in each of said capacitors.

Abstract: Compounds of formula (I) include: X is CH or N, preferably CH; n is 1-5, preferably 1-2; m is 0-5, preferably 1-2; and, when m is 2-5, two of the R2 radicals taken together with two adjacent carbons of the benzene ring can form a 5- or 6-membered heterocyclic ring fused with the benzene ring. Compounds of formula (I) are heme-regulated inhibitor (HRI) activators and useful for prevention or treatment of cardiometabolic diseases such as metabolic syndrome, obesity, insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, steatosis, non-alcoholic steatohepatitis, hypertension, dyslipidemia, atherosclerosis, and heart disease.

Abstract: A bioreactor for cell co-culture having at least first and second cell culture chambers which are separated by a porous membrane. The membrane has at least one sealing gasket integrated in the membrane and being integral therewith. The sealing gasket defines a closed perimeter delimiting a first cell culture area.

Abstract: The method comprises identifying, in a 3D volume, a zone of a first type (H), a zone of a second type (BZ) and a zone of a third type (C) and: —automatically identifying as a candidate channel (bz) a path running through the zone of a second type (BZ) and extending between two points of the zone of a first type (H); and—automatically performing, on a topological space (H_and_BZ_topo), homotopic operations between the candidate channel (bz) and paths (h) running only through the zone of a first type (H), and if the result of said homotopic operations is that the candidate channel (bz) is not homotopic to any path running only through the zone of a first type (H) identifying the candidate channel (bz) as a constrained channel. The computer program product implements the steps of the method of the invention.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: The present invention relates to 1-[1-(benzoyl )-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

Abstract: The invention relates to a light emitting device comprising a light source array which comprises a plurality of separately electrically controllable electric light sources which are arranged in a matrix structure or any other defined geometrical arrangement. Advantageously, the pixel pitch of the light source array is less than (500) nanometer. The invention further relates to an optical detection device comprising a light detection device, which is arranged for producing an electrical signal in response to light reaching a light detection side of the light detection device, and to a method for operating such an optical detection device. The invention further relates to a computer program with program coding means arranged for performing such a method.

Abstract: The present invention concerns subject matter connected to or making use of IgLON5, IgLON5 fragments and variants of IgLON5 and IgLON5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to IgLON5, an IgLON5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide.